



MRC
Prion
Unit



UCL

Generation of Humanised STX6 Overexpression Mice to Study Prion Disease Genetic Risk and as a Model for Therapeutic Intervention

Dr Thomas Cunningham
Prof Simon Mead
Elizabeth Hill

MRC Prion Unit & UCL Institute of Prion Diseases, London, UK



20th July 2024



Syntaxin-6 (STX6)

➤ What is Stx6?

- A protein that regulates transport of proteins and other molecules around cells
- e.g. helps to transport cargo for recycling or degradation, or delivery of cargo to different parts of the cell



Syntaxin-6 (*STX6*)

➤ What is Stx6?

- A protein that regulates transport of proteins and other molecules around cells
- e.g. helps to transport cargo for recycling or degradation, or delivery of cargo to different parts of the cell

➤ Why study Stx6?

- Human genetics studies have linked an *STX6* gene variant to risk of developing sporadic CJD
- People with the risk variant → 16% higher chance of developing sCJD & produce higher levels of STX6



Syntaxin-6 (STX6)

➤ What is Stx6?

- A protein that regulates transport of proteins and other molecules around cells
- e.g. helps to transport cargo for recycling or degradation, or delivery of cargo to different parts of the cell

➤ Why study Stx6?

- Human genetics studies have linked an *STX6* gene variant to risk of developing sporadic CJD
- People with the risk variant → 16% higher chance of developing sCJD & produce higher levels of STX6



Mouse genetics



➤ Why use mouse models

- 98% of genes in humans are also present in mice, and most perform the same function
- Mouse models of prion disease recapitulate hallmarks of the human disease, in a short timeframe
- We can relatively easily genetically modify mice to model human genetics findings



Stx6 “knockout” mice ($Stx6^{-/-}$)


Single cell embryo microinjection



Embryo re-implantation & birth of modified mice




Breed to maintain modified line



Stx6 “knockout” mice (*Stx6*^{-/-})


- Removal of *Stx6* has no meaningful impact in mice infected with a high dose of prions (1%)



- *Stx6*^{-/-} mice develop prion disease within a similar timeframe to controls
- Similar levels of infectivity throughout disease
- Similar changes in the brain


Stx6 “knockout” mice ($Stx6^{-/-}$)

➤ What could we be missing?





➤ 1% is a very high dose!

- 100% of mice get disease
- We can model later disease stages very well
- Not ideal to investigate disease initiation



Stx6 “knockout” mice (*Stx6*^{-/-})


- **Serial dilution experiment: dilute prions up to 1 million x, before infection**
 - At very low doses we can measure how Stx6 impacts establishment of early disease
 - How many mice become infected as we dilute down (“attack rate”)?



- Stx6 lowering is protective at very low doses of infection
 - We think the effect acts early in disease

Stx6 cell models




- We can also change Stx6 levels in cells in a dish, and measure the effect on prion infection




- Altering Stx6 changes the distribution of prion protein
 - Consistent with a role in cell transport

Stx6 overexpression mouse model


Single cell embryo microinjection



Adding extra copies of the Stx6 gene to mimic the risk affect




Embryo re-implantation & birth of modified mice



➤ New lines generated with 3x, 5x, & 15x copies of Stx6

Summary and Conclusions

- Genetic variation in the gene Syntaxin-6 (STX6) increases levels of the gene and protein and increases risk for developing sCJD.



- STX6 is involved in trafficking proteins and other molecules within cells.
- Removal of mouse Stx6 has a modest protective effect – most prominent when mice are infected with a very low concentration of prions, indicating the effect may lie with how brain cells deal with very early infection.
- Cell-culture studies show a change in cell distribution, consistent with a role in cell transport.
- STX6 lowering does not appear to be a promising candidate for treating established prion disease. Protective effects during very early disease stages require further investigation to better understand the cellular mechanisms.
- We have engineered new mouse models for studying how increased Stx6 levels affects prion disease, to mirror the effect of the risk variant in humans, and to compliment our mouse studies investigating Stx6 removal.

Acknowledgements



MRC
Prion
Unit



UCL

MRC Prion Unit

UCL Institute of Prion Diseases



The Michael H. Cole Memorial Research Grant,
contributed by Jeanne Cole

The Daniel L. Dolgin Celebration Grant,
contributed by his family

The Fred Glavan/Lee Gallagher Family Memorial Grant,
contributed by the Glavan and Gallagher families

The Ross Melamed Memorial Grant,
contributed by Olivia Melamed and family and friends

The Andy Lewis Memorial Grant,
contributed by his daughters, extended family, and friends

The José A. Piriz and Sonia E. Piriz Memorial Research Grant,
contributed by Karla Piriz and Lauren

The Tom Stivison Memorial Research Grant,
contributed by Sandra (Cookie) Stivison

The Strides for CJD Grant,
contributed by the Families of the CJD Foundation



Lizzie Hill

Simon Mead lab

Klöhn lab

Cunningham lab:
Andy Tomlinson
Tatiana Jakubcova
Shyma Hamdan

Biological services
facility

Histology facility



Medical
Research
Council